[{"edinetCode":"E00929","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":862.0,"averageTemporaryStaff":112.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":10457000.0,"sharesOwendPercent":0.3421,"outstandingShares":null,"numberOfSubsidiary":3.0,"bps":1413.51,"equityRatio":0.598,"cashAndCashEquivalents":14761000000.0,"assets":66126000000.0,"currentAssets":37059000000.0,"fixedAsset":29067000000.0,"tangibleFixedAssets":12829000000.0,"intangibleFixedAssets":3491000000.0,"investmentAndOtherAssets":12746000000.0,"liabilities":26615000000.0,"currentLiabilities":16253000000.0,"shorTermDept":450000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":750000000.0,"fixedLiabilities":10361000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2500000000.0,"netAsset":39511000000.0,"capitalStock":36965000000.0,"capital":1197000000.0,"capitalSurplus":851000000.0,"accumulatedEarnings":37312000000.0,"treasuryStock":-2396000000.0,"valuationAndConversionAdjustments":2545000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":48527000000.0,"costOfSales":29614000000.0,"grossProfit":18913000000.0,"sgaExpenses":17119000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":4970000000.0,"operatingIncome":1793000000.0,"nonOperatingIncome":441000000.0,"nonOperatingExpenses":232000000.0,"interestExpense":19000000.0,"ordinaryProfit":2002000000.0,"extraordinaryGain":2558000000.0,"extraordinaryLoss":1260000000.0,"incomeBeforeTax":3300000000.0,"incomeTaxes":356000000.0,"netIncome":2944000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2944000000.0,"comprehensiveIncome":3927000000.0,"eps":105.39,"dilutedEps":null,"dividendPerShare":null,"per":15.5,"roe":0.078,"cashFlowFromOperatingActivities":12063000000.0,"depreciationAndCashflowFromOperatingActivities":2447000000.0,"cashFlowFromInvestingActivities":-378000000.0,"cashFlowFromFinancialActivities":-2384000000.0,"changesInCashAndCashEquivalents":9299000000.0,"列1":"asr","submitDate":"2017\/6\/29","stockCode":4514,"accountingYear":"第97期（自　平成28年４月１日　至　平成29年３月31日）","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00929","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1197,"settlementDate":"2022\/3\/31","submitterName":"あすか製薬株式会社","submitterNameEnglish":"ASKA pharmaceutical Co., Ltd.","submitterNameKana":"アスカセイヤクカブシキガイシャ","location":"港区芝浦二丁目５番１号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00929","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":856.0,"averageTemporaryStaff":120.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":9721000.0,"sharesOwendPercent":0.3448,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":1509.7,"equityRatio":0.6426,"cashAndCashEquivalents":10346000000.0,"assets":66235000000.0,"currentAssets":35792000000.0,"fixedAsset":30442000000.0,"tangibleFixedAssets":12091000000.0,"intangibleFixedAssets":3334000000.0,"investmentAndOtherAssets":15016000000.0,"liabilities":23675000000.0,"currentLiabilities":14214000000.0,"shorTermDept":450000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":750000000.0,"fixedLiabilities":9460000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1750000000.0,"netAsset":42559000000.0,"capitalStock":39052000000.0,"capital":1197000000.0,"capitalSurplus":851000000.0,"accumulatedEarnings":39280000000.0,"treasuryStock":-2278000000.0,"valuationAndConversionAdjustments":3507000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":48944000000.0,"costOfSales":30059000000.0,"grossProfit":18884000000.0,"sgaExpenses":16060000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":4055000000.0,"operatingIncome":2824000000.0,"nonOperatingIncome":414000000.0,"nonOperatingExpenses":164000000.0,"interestExpense":14000000.0,"ordinaryProfit":3073000000.0,"extraordinaryGain":null,"extraordinaryLoss":10000000.0,"incomeBeforeTax":3063000000.0,"incomeTaxes":674000000.0,"netIncome":2388000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2388000000.0,"comprehensiveIncome":3350000000.0,"eps":84.8,"dilutedEps":null,"dividendPerShare":null,"per":19.72,"roe":0.0582,"cashFlowFromOperatingActivities":76000000.0,"depreciationAndCashflowFromOperatingActivities":2324000000.0,"cashFlowFromInvestingActivities":-3348000000.0,"cashFlowFromFinancialActivities":-1142000000.0,"changesInCashAndCashEquivalents":-4415000000.0,"列1":"asr","submitDate":"2018\/6\/28","stockCode":4514,"accountingYear":"第98期（自　平成29年４月１日　至　平成30年３月31日）","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00929","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1197,"settlementDate":"2022\/3\/31","submitterName":"あすか製薬株式会社","submitterNameEnglish":"ASKA pharmaceutical Co., Ltd.","submitterNameKana":"アスカセイヤクカブシキガイシャ","location":"港区芝浦二丁目５番１号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00929","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":842.0,"averageTemporaryStaff":123.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":10832000.0,"sharesOwendPercent":0.3806,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":1538.75,"equityRatio":0.529,"cashAndCashEquivalents":11107000000.0,"assets":82194000000.0,"currentAssets":37829000000.0,"fixedAsset":44365000000.0,"tangibleFixedAssets":13573000000.0,"intangibleFixedAssets":15332000000.0,"investmentAndOtherAssets":15458000000.0,"liabilities":38738000000.0,"currentLiabilities":18002000000.0,"shorTermDept":450000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":3048000000.0,"fixedLiabilities":20735000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":12970000000.0,"netAsset":43456000000.0,"capitalStock":40460000000.0,"capital":1197000000.0,"capitalSurplus":913000000.0,"accumulatedEarnings":40630000000.0,"treasuryStock":-2281000000.0,"valuationAndConversionAdjustments":2995000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":46706000000.0,"costOfSales":27814000000.0,"grossProfit":18891000000.0,"sgaExpenses":17107000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":4493000000.0,"operatingIncome":1782000000.0,"nonOperatingIncome":481000000.0,"nonOperatingExpenses":283000000.0,"interestExpense":41000000.0,"ordinaryProfit":1980000000.0,"extraordinaryGain":106000000.0,"extraordinaryLoss":203000000.0,"incomeBeforeTax":1883000000.0,"incomeTaxes":138000000.0,"netIncome":1744000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1744000000.0,"comprehensiveIncome":1232000000.0,"eps":61.81,"dilutedEps":null,"dividendPerShare":null,"per":18.54,"roe":0.041,"cashFlowFromOperatingActivities":2504000000.0,"depreciationAndCashflowFromOperatingActivities":2491000000.0,"cashFlowFromInvestingActivities":-14780000000.0,"cashFlowFromFinancialActivities":13036000000.0,"changesInCashAndCashEquivalents":760000000.0,"列1":"asr","submitDate":"2019\/6\/27","stockCode":4514,"accountingYear":"第99期（自　2018年４月１日　至　2019年３月31日）","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00929","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1197,"settlementDate":"2022\/3\/31","submitterName":"あすか製薬株式会社","submitterNameEnglish":"ASKA pharmaceutical Co., Ltd.","submitterNameKana":"アスカセイヤクカブシキガイシャ","location":"港区芝浦二丁目５番１号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00929","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.501,"cashAndCashEquivalents":null,"assets":84256000000.0,"currentAssets":39856000000.0,"fixedAsset":44399000000.0,"tangibleFixedAssets":14128000000.0,"intangibleFixedAssets":14869000000.0,"investmentAndOtherAssets":15401000000.0,"liabilities":42025000000.0,"currentLiabilities":21123000000.0,"shorTermDept":7323000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":20902000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":13095000000.0,"netAsset":42230000000.0,"capitalStock":39521000000.0,"capital":1197000000.0,"capitalSurplus":913000000.0,"accumulatedEarnings":39674000000.0,"treasuryStock":-2264000000.0,"valuationAndConversionAdjustments":2709000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":13991000000.0,"costOfSales":7361000000.0,"grossProfit":6629000000.0,"sgaExpenses":5791000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":837000000.0,"nonOperatingIncome":180000000.0,"nonOperatingExpenses":48000000.0,"interestExpense":13000000.0,"ordinaryProfit":969000000.0,"extraordinaryGain":49000000.0,"extraordinaryLoss":110000000.0,"incomeBeforeTax":907000000.0,"incomeTaxes":344000000.0,"netIncome":563000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":563000000.0,"comprehensiveIncome":277000000.0,"eps":19.96,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/9","stockCode":4514,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00929","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1197,"settlementDate":"2022\/3\/31","submitterName":"あすか製薬株式会社","submitterNameEnglish":"ASKA pharmaceutical Co., Ltd.","submitterNameKana":"アスカセイヤクカブシキガイシャ","location":"港区芝浦二丁目５番１号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00929","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":11076000.0,"sharesOwendPercent":0.3887,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.509,"cashAndCashEquivalents":7291000000.0,"assets":82766000000.0,"currentAssets":38951000000.0,"fixedAsset":43814000000.0,"tangibleFixedAssets":14036000000.0,"intangibleFixedAssets":14373000000.0,"investmentAndOtherAssets":15404000000.0,"liabilities":40628000000.0,"currentLiabilities":20381000000.0,"shorTermDept":7323000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":20247000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":12570000000.0,"netAsset":42137000000.0,"capitalStock":39595000000.0,"capital":1197000000.0,"capitalSurplus":928000000.0,"accumulatedEarnings":39687000000.0,"treasuryStock":-2219000000.0,"valuationAndConversionAdjustments":2542000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":26582000000.0,"costOfSales":14492000000.0,"grossProfit":12089000000.0,"sgaExpenses":11343000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":2459000000.0,"operatingIncome":746000000.0,"nonOperatingIncome":230000000.0,"nonOperatingExpenses":107000000.0,"interestExpense":31000000.0,"ordinaryProfit":869000000.0,"extraordinaryGain":49000000.0,"extraordinaryLoss":null,"incomeBeforeTax":918000000.0,"incomeTaxes":341000000.0,"netIncome":577000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":577000000.0,"comprehensiveIncome":124000000.0,"eps":20.42,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-5330000000.0,"depreciationAndCashflowFromOperatingActivities":1788000000.0,"cashFlowFromInvestingActivities":-1739000000.0,"cashFlowFromFinancialActivities":3253000000.0,"changesInCashAndCashEquivalents":-3815000000.0,"列1":"q2r","submitDate":"2019\/11\/8","stockCode":4514,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00929","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1197,"settlementDate":"2022\/3\/31","submitterName":"あすか製薬株式会社","submitterNameEnglish":"ASKA pharmaceutical Co., Ltd.","submitterNameKana":"アスカセイヤクカブシキガイシャ","location":"港区芝浦二丁目５番１号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00929","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.515,"cashAndCashEquivalents":null,"assets":83639000000.0,"currentAssets":40037000000.0,"fixedAsset":43602000000.0,"tangibleFixedAssets":13771000000.0,"intangibleFixedAssets":13886000000.0,"investmentAndOtherAssets":15943000000.0,"liabilities":40570000000.0,"currentLiabilities":21123000000.0,"shorTermDept":7948000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":19447000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":11695000000.0,"netAsset":43069000000.0,"capitalStock":39901000000.0,"capital":1197000000.0,"capitalSurplus":928000000.0,"accumulatedEarnings":39976000000.0,"treasuryStock":-2201000000.0,"valuationAndConversionAdjustments":3167000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":41207000000.0,"costOfSales":22643000000.0,"grossProfit":18563000000.0,"sgaExpenses":17043000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":1520000000.0,"nonOperatingIncome":375000000.0,"nonOperatingExpenses":163000000.0,"interestExpense":48000000.0,"ordinaryProfit":1731000000.0,"extraordinaryGain":49000000.0,"extraordinaryLoss":132000000.0,"incomeBeforeTax":1648000000.0,"incomeTaxes":583000000.0,"netIncome":1064000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1064000000.0,"comprehensiveIncome":1237000000.0,"eps":37.66,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/10","stockCode":4514,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00929","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1197,"settlementDate":"2022\/3\/31","submitterName":"あすか製薬株式会社","submitterNameEnglish":"ASKA pharmaceutical Co., Ltd.","submitterNameKana":"アスカセイヤクカブシキガイシャ","location":"港区芝浦二丁目５番１号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00929","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":807.0,"averageTemporaryStaff":119.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":10877000.0,"sharesOwendPercent":0.3817,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":1467.58,"equityRatio":0.5181,"cashAndCashEquivalents":7294000000.0,"assets":80239000000.0,"currentAssets":37326000000.0,"fixedAsset":42913000000.0,"tangibleFixedAssets":13539000000.0,"intangibleFixedAssets":13584000000.0,"investmentAndOtherAssets":15789000000.0,"liabilities":38665000000.0,"currentLiabilities":17127000000.0,"shorTermDept":450000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":2298000000.0,"fixedLiabilities":21537000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":13671000000.0,"netAsset":41573000000.0,"capitalStock":39495000000.0,"capital":1197000000.0,"capitalSurplus":928000000.0,"accumulatedEarnings":39560000000.0,"treasuryStock":-2191000000.0,"valuationAndConversionAdjustments":2078000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":52542000000.0,"costOfSales":28525000000.0,"grossProfit":24016000000.0,"sgaExpenses":22509000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":4913000000.0,"operatingIncome":1507000000.0,"nonOperatingIncome":424000000.0,"nonOperatingExpenses":216000000.0,"interestExpense":64000000.0,"ordinaryProfit":1715000000.0,"extraordinaryGain":49000000.0,"extraordinaryLoss":862000000.0,"incomeBeforeTax":901000000.0,"incomeTaxes":252000000.0,"netIncome":649000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":649000000.0,"comprehensiveIncome":-267000000.0,"eps":22.96,"dilutedEps":null,"dividendPerShare":null,"per":47.82,"roe":0.0153,"cashFlowFromOperatingActivities":-492000000.0,"depreciationAndCashflowFromOperatingActivities":3669000000.0,"cashFlowFromInvestingActivities":-2927000000.0,"cashFlowFromFinancialActivities":-392000000.0,"changesInCashAndCashEquivalents":-3812000000.0,"列1":"asr","submitDate":"2020\/6\/25","stockCode":4514,"accountingYear":"第100期（自　2019年４月１日　至　2020年３月31日）","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00929","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1197,"settlementDate":"2022\/3\/31","submitterName":"あすか製薬株式会社","submitterNameEnglish":"ASKA pharmaceutical Co., Ltd.","submitterNameKana":"アスカセイヤクカブシキガイシャ","location":"港区芝浦二丁目５番１号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00929","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.527,"cashAndCashEquivalents":null,"assets":80166000000.0,"currentAssets":37952000000.0,"fixedAsset":42213000000.0,"tangibleFixedAssets":13328000000.0,"intangibleFixedAssets":13070000000.0,"investmentAndOtherAssets":15814000000.0,"liabilities":37892000000.0,"currentLiabilities":17226000000.0,"shorTermDept":4448000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":20666000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":12796000000.0,"netAsset":42273000000.0,"capitalStock":39967000000.0,"capital":1197000000.0,"capitalSurplus":928000000.0,"accumulatedEarnings":40015000000.0,"treasuryStock":-2174000000.0,"valuationAndConversionAdjustments":2306000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":13714000000.0,"costOfSales":7640000000.0,"grossProfit":6073000000.0,"sgaExpenses":5175000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":898000000.0,"nonOperatingIncome":171000000.0,"nonOperatingExpenses":81000000.0,"interestExpense":14000000.0,"ordinaryProfit":987000000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":987000000.0,"incomeTaxes":248000000.0,"netIncome":739000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":739000000.0,"comprehensiveIncome":966000000.0,"eps":26.09,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/7","stockCode":4514,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00929","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1197,"settlementDate":"2022\/3\/31","submitterName":"あすか製薬株式会社","submitterNameEnglish":"ASKA pharmaceutical Co., Ltd.","submitterNameKana":"アスカセイヤクカブシキガイシャ","location":"港区芝浦二丁目５番１号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00929","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":11236000.0,"sharesOwendPercent":0.3943,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.542,"cashAndCashEquivalents":8352000000.0,"assets":79445000000.0,"currentAssets":37809000000.0,"fixedAsset":41636000000.0,"tangibleFixedAssets":13165000000.0,"intangibleFixedAssets":12561000000.0,"investmentAndOtherAssets":15908000000.0,"liabilities":36374000000.0,"currentLiabilities":15702000000.0,"shorTermDept":2198000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":20672000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":12772000000.0,"netAsset":43070000000.0,"capitalStock":40792000000.0,"capital":1197000000.0,"capitalSurplus":928000000.0,"accumulatedEarnings":40828000000.0,"treasuryStock":-2161000000.0,"valuationAndConversionAdjustments":2277000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":27403000000.0,"costOfSales":14563000000.0,"grossProfit":12840000000.0,"sgaExpenses":10894000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":2338000000.0,"operatingIncome":1946000000.0,"nonOperatingIncome":201000000.0,"nonOperatingExpenses":194000000.0,"interestExpense":29000000.0,"ordinaryProfit":1952000000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":1952000000.0,"incomeTaxes":400000000.0,"netIncome":1552000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1552000000.0,"comprehensiveIncome":1751000000.0,"eps":54.77,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":3311000000.0,"depreciationAndCashflowFromOperatingActivities":1797000000.0,"cashFlowFromInvestingActivities":-531000000.0,"cashFlowFromFinancialActivities":-1722000000.0,"changesInCashAndCashEquivalents":1057000000.0,"列1":"q2r","submitDate":"2020\/11\/9","stockCode":4514,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00929","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1197,"settlementDate":"2022\/3\/31","submitterName":"あすか製薬株式会社","submitterNameEnglish":"ASKA pharmaceutical Co., Ltd.","submitterNameKana":"アスカセイヤクカブシキガイシャ","location":"港区芝浦二丁目５番１号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00929","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.525,"cashAndCashEquivalents":null,"assets":83542000000.0,"currentAssets":42823000000.0,"fixedAsset":40719000000.0,"tangibleFixedAssets":12974000000.0,"intangibleFixedAssets":12231000000.0,"investmentAndOtherAssets":15512000000.0,"liabilities":39692000000.0,"currentLiabilities":17780000000.0,"shorTermDept":2848000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":21912000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":13897000000.0,"netAsset":43849000000.0,"capitalStock":41507000000.0,"capital":1197000000.0,"capitalSurplus":928000000.0,"accumulatedEarnings":41527000000.0,"treasuryStock":-2147000000.0,"valuationAndConversionAdjustments":2342000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":43350000000.0,"costOfSales":23023000000.0,"grossProfit":20326000000.0,"sgaExpenses":16550000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":3776000000.0,"nonOperatingIncome":325000000.0,"nonOperatingExpenses":874000000.0,"interestExpense":44000000.0,"ordinaryProfit":3227000000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":3227000000.0,"incomeTaxes":776000000.0,"netIncome":2451000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2451000000.0,"comprehensiveIncome":2715000000.0,"eps":86.47,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/8","stockCode":4514,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00929","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1197,"settlementDate":"2022\/3\/31","submitterName":"あすか製薬株式会社","submitterNameEnglish":"ASKA pharmaceutical Co., Ltd.","submitterNameKana":"アスカセイヤクカブシキガイシャ","location":"港区芝浦二丁目５番１号","industory":"医薬品","corporateNumber":9010000000000.0}]